By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Soligenix 

29 Emmons Drive
Suite C-10
Princeton  New Jersey  08540  U.S.A.
Phone: 609-538-8200 Fax: 609-452-6467


SEARCH JOBS








Company News
Soligenix (SNGX) Receives Additional National Institute of Allergy And Infectious Diseases (NIAID) Funding To Advance Development of OrbeShield In GI ARS 8/27/2015 6:17:51 AM
Soligenix (SNGX) Receives Additional National Institute of Allergy And Infectious Diseases (NIAID) Funding To Advance Development Of Heat Stable Ricin Vaccine 8/19/2015 6:48:30 AM
Soligenix (SNGX) Announces Recent Highlights and Second Quarter 2015 Financial Results 8/12/2015 7:52:36 AM
Soligenix (SNGX) Receives Orphan Drug Designation From The European Commission (EC) For SGX301 As A Treatment For Cutaneous T-Cell Lymphoma 8/4/2015 6:07:21 AM
Soligenix (SNGX) Enters Into A $10 Million Equity Purchase Agreement 8/3/2015 6:31:37 AM
Soligenix (SNGX) Announces Collaboration With The National Organization for Rare Disorders And The Cutaneous Lymphoma Foundation In Advancing Its Phase 3 Study Of SGX301 For The Treatment Of Cutaneous T-Cell Lymphoma 6/23/2015 7:15:29 AM
Soligenix (SNGX) Announces Publication Of Successful Application Of Its Heat Stabilization Technology To A Human Papillomavirus Vaccine 6/2/2015 6:15:33 AM
Soligenix (SNGX) Announces Collaboration With The University Of Hawai'i At Manoa And Hawaii Biotech To Develop Heat Stable Ebola Vaccine 5/28/2015 6:24:49 AM
Soligenix (SNGX) Announces First Quarter 2015 Highlights And Financial Results 5/14/2015 10:38:43 AM
Soligenix (SNGX) Announces Development Agreement With Emergent BioSolutions (EBS) 5/13/2015 6:40:15 AM
12345678910...
//-->